Drug
Itacitinib clinical trials
Also written INCB039110.
- studies test it
- 47
- open now
- 3
- in phase 3
- 2
- first study started
- 2012
Keep track of what changes. Save the itacitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
47 studies that test it; most in 2020 (8)
| Year | Studies |
|---|---|
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 8 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 22
- Phase 2
- 33
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 23
Incyte Corporation (23) · M.D. Anderson Cancer Center (4) · University of Pennsylvania (2) · Assistance Publique - Hôpitaux de Paris (2) · Washington University School of Medicine (2) · City of Hope Medical Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Fondazione per la Medicina Personalizzata (1)
Often tested with
Tested in the same studies.
Parsaclisib (2) · Ruxolitinib (2) · Ibrutinib (2) · Everolimus (2) · Dezapelisib (2) · Cyclophosphamide (1) · Tacrolimus (1) · Erlotinib (1)
Studies
Open first, then newest update. How each study uses itacitinib is read from its arms, and is right about nine times in ten.
Testing it · 47
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05757219Written as Itacitinib
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)RecruitingPhase 1/2Michael SavonaNCT04061421Written as Itacitinib
- Safety and Efficacy of Itacitinib in Adults With Systemic SclerosisRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT04789850Written as Itacitinib
- Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingPhase 2City of Hope Medical CenterNCT05364762Written as Itacitinib
- Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04859946Written as Itacitinib
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05823571Written as Itacitinib
- A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedPhase 2Incyte CorporationNCT04640025Written as itacitinib
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingPhase 2Incyte CorporationNCT04509700Written as parsaclisib + itacitinib
- Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingPhase 1/2University of PennsylvaniaNCT03697408Written as Itacitinib
- Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesCompletedPhase 1Incyte CorporationNCT01905813Written as INCB040093 + itacitinib
- Itacitinib in Advanced Hepatocellular CarcinomaCompletedPhase 1Imperial College LondonNCT04358185Written as Itacitinib
- Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint InhibitorsWithdrawnPhase 2Douglas JohnsonNCT05660421Written as Itacitinib
- Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedPhase 2Incyte CorporationNCT02257619Written as Itacitinib
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedPhase 1/2Incyte CorporationNCT02917993Written as Itacitinib
- Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIBCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT05063110Written as Itacitinib
- Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantTerminatedPhase 1M.D. Anderson Cancer CenterNCT04239989Written as Itacitinib
- Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedPhase 1/2Incyte CorporationNCT03721965Written as Itacitinib
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedPhase 1Incyte CorporationNCT03320642Written as Itacitinib
- GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedPhase 2/3Incyte CorporationNCT03584516Written as Itacitinib
- Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationTerminatedPhase 1/2Incyte CorporationNCT03978637Written as Itacitinib
See all 47 studies that test itacitinib →
Given in every arm · 4 — itacitinib is usual care beside what is tested
- A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyCompletedPhase 2Incyte CorporationNCT04071366Written as Itacitinib
- A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With MyelofibrosisCompletedPhase 2Incyte CorporationNCT03144687Written as Itacitinib
- An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02265510Written as INCB039110
- Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedPhase 1Incyte CorporationNCT02559492Written as Itacitinib
Codes
What other systems call itacitinib · ClinicalTrials.gg INT001651
- MeSH (NLM) C000718170itacitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 19J3781LPMITACITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27891174itacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116855ItacitinibOne source FDA
- DrugBank DB12154One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718170 | itacitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 19J3781LPM | ITACITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27891174 | itacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116855 | Itacitinib | One source FDA |
| DrugBank | DB12154 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.